Large-Scale Preparation of Recombinant Human Calcitonin from a Multimeric Fusion Protein Produced in Escherichia coli
スポンサーリンク
概要
- 論文の詳細を見る
In order to develop a large-scale, high-yield production process for human calcitonin(hCT)in Escherichia coli, a stable expression plasmid was constructed and the expressed protein was modified for efficient cleavage by protease. Multiple copies of a synthetic gene encoding hCT-Leu-Arg, a substrate for C-terminal amidation by carboxypeptidase Y(CPY), were inserted into the stable expression plasmid. Using this plasmid, the expression of a multimeric fusion protein was induced by shifting the temperature from 34 to 38°C. The multimeric fusion protein was accumulated as inclusion bodies. After the fermentation, the cells were harvested and disrupted by a homogenizer. The insoluble multimeric fusion protein was suspended in 6.6M urea solution. At this time, however, the protein could not be solubilized and thus the efficiency of cleavage by protease was low. To solubilize the protein and protect Lys residues against digestion by trypsin, the protein was citraconilated with citraconic anhydride. Following S-sulfornation with Na_2SO_3-CuSO_4, almost all the protein was solubilized. The solubilized, citraconilated, and S-sulfonated protein was digested with trypsin efficiently. By treatment with trypsin, the multimeric fusion protein was cleaved into monomers of citraconilated and S-sulfonated hCT-Leu-Arg (S-hCT-Leu-Arg). The subsequent decitraconilation was performed at low pH. S-hCT-Leu-Arg, isolated by preparative HPLC, was directly converted into S-hCT-HN_2 by CPY without removal of the Arg residue. Finally, S-hCT-HN_2 was desulfonated and converted into mature hCT. In this way, a large amount of recombinant mature hCT was obtained in a tank fermentation. To our knowledge, this is the first report of industrial-scale, human calcitonin production using a multimeric fusion protein expression system.
- 社団法人日本生物工学会の論文
- 1999-03-25
著者
-
YAO Yoshio
Biomedical Research Laboratories, Sankyo Co. Ltd.
-
Fukui Fumio
Biomedical Research Laboratories Sankyo Co.ltd.
-
Yao Yoshio
Biomedical Research Laboratories Sankyo Co. Ltd.
-
Yao Yoshio
Biomedical Research Laboratories Sankyo Co.ltd.
-
YOSHIKAWA Hiroji
Biomedical Research Laboratories, Sankyo Co., Ltd.
-
ISHIKAWA HIROKAZU
Pharamacology and Molecular Biology Research Laboratories, Sankyo Co.Ltd.
-
KAWAGUCHI JUNKO
Biomedical Research Laboratories, Sankyo Co.Ltd.
-
TAMAOKI HIDETSUNE
Biomedical Research Laboratories, Sankyo Co.Ltd.
-
ONO TAKESHI
Biomedical Research Laboratories, Sankyo Co.Ltd.
-
Yoshikawa Hiroji
Biomedical Research Laboratories Sankyo Co.ltd.
-
Yoshikawa Hiroji
Biomedical Research Laboratories Sankyo Co. Ltd.
-
Ishikawa Hirokazu
Pharamacology And Molecular Biology Research Laboratories Sankyo Co.ltd.
-
Tamaoki Hidetsune
Biomedical Research Laboratories Sankyo Co.ltd.
-
Ono T
Biomedical Research Laboratories Sankyo Co.ltd.
-
Kawaguchi Junko
Biomedical Research Laboratories Sankyo Co.ltd.
-
Kawaguchi Junko
Biomedical Research Laboratories Sankyo Co. Ltd.
関連論文
- Direct Formation of Human Interleukin-11 by Cis-Acting System of Plant Virus Protease in Escherichia coli
- Bioconversion of Milbemycin-related Compounds: Biosynthetic Pathway of Milbemycins
- Bioconversion of Milbemycin-related Compounds: Isolation and Utilization of Non-producer, Strain RNBC-5-51
- Fermentative production of milbemycin α_ and α_ : Appearance of morphological mutants during large-scale fermentation
- Molecular Cloning and Expression of the Gene Encoding a Phospholipase A_1 from Aspergillus oryzae
- Large-Scale Preparation of Recombinant Human Calcitonin from a Multimeric Fusion Protein Produced in Escherichia coli
- Synthetic Strategy for Long Peptides
- Isolation and Characterization of the Gene Conferring Thiamine-inducible Expression from Saccharomyces cerevisiae
- Extracellular Processing of Carboxypeptidase Y Secreted by a Saccharomyces cerevisiae ssl1 Mutant Strain
- 殺ダニ剤ミルベメクチンの開発〔含 英文〕